留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

陈自强,  张玮,  李玉平,  王晓宇

downloadPDF
文章导航 > 药学实践与服务  > 2016 >  34(2): 103-105
陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
引用本文: 陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
shu
CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
Citation: CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
shu

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002
  • 1.

    第二军医大学附属长海医院骨科, 上海 200433

  • 2.

    同济大学附属上海市肺科医院药剂科, 上海 200433

  • 3.

    第二军医大学附属长海医院药学部, 上海 200433

Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma

  • 1.

    Department of Orthopaedics, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • 2.

    Department of Pharmacy, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China

  • 3.

    Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • 摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。
    Abstract: Multidrug resistance(MDR) of tumor cell is the major problem for chemotherapy. However, there is no effective strategy to overcome MDR due to the complicated mechanism. The nano-sized drug delivery system could target to the tumor cell. Moreover, it could delivery different kinds of drugs. Therefore, the nano-sized drug delivery system has become a promising approach to reverse MDR. The nano-sized drug delivery system which is applied to treat the MDR of tumor(osteosarcoma) was summarized and the reverse mechanism was discussed.
  • [1] Palakurthi S, Yellepeddi VK, Vangara KK. Recent trends in cancer drug resistance reversal strategies using nanoparticles[J]. Expert Opin Drug Deliv, 2012, 9(3):287-301.
    [2] Shapira A, LivneyY D, Broxterman H J, et al. Nanomedicine for targeted cancer therapy:towards the overcoming of drug resistance[J]. Drug Resist Updat, 2011, 14(3):150-163.
    [3] Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance[J]. Biomaterials, 2010, 31(2):358-365.
    [4] Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA nanoparticles[J]. Eur J Pharm Sci, 2009, 37(3-4):300-305.
    [5] Khdair A, Handa H, Mao GZ, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro[J]. Eur J Pharm Biopharm, 2009, 71(2):214-222.
    [6] Lee ES, Gao ZG, Kim D, et a1. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e)specific TAT exposure and multidrug resistance[J]. J Control Rel, 2008, 129(3):228.
    [7] Chen B, Sun Q, Wang X, et al. Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells[J]. Int J Nanomedicine, 2008, 3(2):277-286.
    [8] Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells[J]. Int J Nanomedicine, 2009, 4:65-71.
    [9] Chen BA, Lai BB, Cheng J, et al. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo[J]. Int J Nanomed, 2009, 4:201-208.
    [10] Chen AM, Zhang M, Wei DG, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells[J]. Small, 2009, 5(23):2673-2677.
    [11] WangY, Saad M, Pakunlu RI, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor[J]. Clin Cancer Res, 2008, 14(11):3607-3616.
    [12] Devalapally H, Duan ZF, Seiden MV, et al. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles[J]. Clin Cancer Res, 2008,14(10):3193-3203.
    [13] Fan L, Li F, Zhang HT, et al. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance[J]. Biomaterials, 2010, 31(21):5634-5642.
    [14] Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. BMC Cancer,2009, 9:399.
    [15] Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1(MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. PLoS One, 2010, 5(5):e10764.
  • [1] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [2] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 1-4. doi: 10.12206/j.issn.2097-2024.202401002
    [3] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404082
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2624
  • HTML全文浏览量:  264
  • PDF下载量:  14
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-12-21
  • 修回日期:  2015-05-06

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002
  • 1. 第二军医大学附属长海医院骨科, 上海 200433
  • 2. 同济大学附属上海市肺科医院药剂科, 上海 200433
  • 3. 第二军医大学附属长海医院药学部, 上海 200433
  • 收稿日期: 2014-12-21
  • 修回日期: 2015-05-06

摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。

English Abstract

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
引用本文: 陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
shu
CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
Citation: CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
shu

    全文HTML

参考文献 (15)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计